FGF2-related methods for diagnosing and treating depression

• Main Authors: MENG, FAN, SCHATZBERG, ALAN F, EVANS, SIMON J, VAWTER, MARQUIS P, AKIL, HUDA, SCOTT, LAURA J, THOMPSON, ROBERT C, CHOUDARY, PRABHAKARA V, BUNNEY, WILLIAM E. JR, BURMEISTER, MARGIT, JONES, EDWARD G, BOEHNKE, MICHAEL, MYERS, RICHARD M, TURNER, CORTNEY, ABSHER, DEVIN, KERMAN, ILAN, TOMITA, HIROAKI, WATSON, STANLEY J, BERNARD, RENÉ, LI, JUN, LYONS, DAVID MICHAEL
• Format: Patent
• Language: English; French; German
• Published: 24.12.2014
• Subjects: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; DERIVATIVES THEREOF; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; SUGARS; TESTING; VINEGAR; WINE

The present application relates to ligands that activate FGF receptor for use as an antidepressant. The ligand is an NCAM peptide mimetic, which is used to treat major depressive disorder such as anxiety. The invention also relates to administration routes and dosages.